Osiris Therapeutics, Inc. Announces That Results of Stem Cell Trial to Treat Heart Disease will be Presented at American College of Cardiology Conference

BALTIMORE--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (Nasdaq:OSIR) today announced that six-month results from a clinical trial evaluating PROVACEL™, an adult mesenchymal stem cell (MSC) therapy for the treatment of heart disease, will be presented on Sunday, March 25.